What is Wedbush’s Estimate for GLUE FY2029 Earnings?

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) – Stock analysts at Wedbush issued their FY2029 earnings per share estimates for Monte Rosa Therapeutics in a report issued on Thursday, March 20th. Wedbush analyst R. Driscoll expects that the company will post earnings of ($1.33) per share for the year. Wedbush has a “Outperform” rating and a $17.00 price objective on the stock. The consensus estimate for Monte Rosa Therapeutics’ current full-year earnings is ($1.49) per share.

Other equities analysts have also recently issued reports about the stock. Lifesci Capital assumed coverage on shares of Monte Rosa Therapeutics in a research note on Wednesday, March 12th. They set an “outperform” rating and a $19.00 price target for the company. Wells Fargo & Company dropped their target price on Monte Rosa Therapeutics from $11.00 to $10.00 and set an “equal weight” rating on the stock in a report on Friday.

Monte Rosa Therapeutics Price Performance

GLUE opened at $5.83 on Monday. The company has a market capitalization of $358.18 million, a price-to-earnings ratio of -3.19 and a beta of 1.50. The business’s 50-day moving average price is $6.18 and its two-hundred day moving average price is $6.78. Monte Rosa Therapeutics has a 1 year low of $3.21 and a 1 year high of $12.40.

Monte Rosa Therapeutics (NASDAQ:GLUE) last released its quarterly earnings results on Thursday, March 20th. The company reported $0.23 earnings per share for the quarter, beating the consensus estimate of ($0.37) by $0.60. The company had revenue of $14.00 million during the quarter, compared to analyst estimates of $43.73 million.

Institutional Investors Weigh In On Monte Rosa Therapeutics

A number of institutional investors have recently made changes to their positions in the company. Versant Venture Management LLC acquired a new position in shares of Monte Rosa Therapeutics during the 4th quarter worth approximately $39,231,000. BVF Inc. IL bought a new stake in Monte Rosa Therapeutics during the fourth quarter worth about $19,185,000. Vanguard Group Inc. increased its holdings in Monte Rosa Therapeutics by 24.5% in the 4th quarter. Vanguard Group Inc. now owns 3,156,354 shares of the company’s stock valued at $21,905,000 after buying an additional 622,134 shares during the period. Price T Rowe Associates Inc. MD lifted its holdings in shares of Monte Rosa Therapeutics by 7.8% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 7,116,637 shares of the company’s stock worth $49,391,000 after acquiring an additional 515,496 shares during the period. Finally, Norges Bank acquired a new position in Monte Rosa Therapeutics during the fourth quarter valued at approximately $3,094,000. Institutional investors own 79.96% of the company’s stock.

Monte Rosa Therapeutics Company Profile

Monte Rosa Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases.